{
    "relation": [
        [
            "Arms",
            "Experimental: BAF312, 10 mg",
            "Experimental: BAF312, 2 mg",
            "Experimental: BAF312, 0.5 mg",
            "Experimental: BAF312, dose between 0.1- 8 mg blinded",
            "Experimental: BAF312, dose between 0.1- 8 mg blinded."
        ],
        [
            "Assigned Interventions",
            "Drug: BAF312",
            "Drug: BAF312",
            "Drug: BAF312",
            "Drug: BAF312",
            "Drug: BAF312"
        ]
    ],
    "pageTitle": "Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/study/NCT01185821?term=baf+multiple+sclerosis&show_locs=Y",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042981576.7/warc/CC-MAIN-20150728002301-00205-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 859699216,
    "recordOffset": 859688931,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{523=This blinded extension study is designed to offer patients with relapsing-remitting MS having completed the core study CBAF312A2201 access to BAF312 until they can enter an open label study. It will provide data on long-term safety, tolerability and efficacy of BAF312 in this patient population.}",
    "textBeforeTable": "August 2016 (Final data collection date for primary outcome measure) Estimated Primary Completion Date: August 2016 Estimated Study Completion Date: August 2010 Study Start Date: 186 Enrollment: Long-term efficacy on paraclinical ground (neuroradiological measures of neurodegeneration) [\u00a0Time\u00a0Frame:\u00a0up to 15 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Long-term efficacy on clinical ground (relapse rate, disability progression) [\u00a0Time\u00a0Frame:\u00a0up to 15 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Secondary Outcome Measures: Long-term safety and tolerability (emphasis on cardiovascular events, viral infections, macular edema and dermatologic alterations) [\u00a0Time\u00a0Frame:\u00a0up to 15 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0] Primary Outcome Measures: Further study details as provided by Novartis: U.S. FDA Resources Neurologic\u00a0Diseases Multiple\u00a0Sclerosis Autoimmune\u00a0Diseases",
    "textAfterTable": "\u00a0 Eligibility Ages Eligible for Study: \u00a0 18 Years to 56 Years Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 No Criteria Inclusion Criteria: Patients completed the core study BAF312A2201 Written informed consent provided before any assessment of the extension study Female patients at risk of becoming pregnant must have a negative pregnancy test and use simultaneously two forms of effective contraception Exclusion Criteria: Newly diagnosed systemic disease other than MS (which may require immunosuppressive treatment) Malignancies, diabetes, significant cardiovascular and pulmonary diseases and conditions Active infections Other protocol-defined inclusion/exclusion criteria may apply \u00a0 Contacts and Locations Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}